Watchlist

Watchlist
Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. (AGIO)
ASLAN Pharmaceuticals Updates U.S. IPO Plans
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o…
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp…
Agios and Jounce spike on potential Celgene interest
Agios Pharmaceuticals ( AGIO +8.5% ) and Jounce Therapeutics ( JNCE +11.1% ) perk up on the heels of a Financial Times article that they would be attractive takeover targets for deal-hungry Celgene ( CELG +1.1% ). More news on: Agios Pharmaceuticals, Inc., Jounce Therapeutics, Celg…
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to sell ADSs of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an F-1 registration statement . The firm is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents a…
3 Things In Biotech, March 20: Phase 1, 2, 3 Moves For Novo, Heron And Agios
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Novo Nordisk unveils new weight loss study results at ENDO Company: Novo Nordisk ( NVO ) …
Biotechs Approaching New Waters
Biotech Pulse Biotech stocks are now approaching the highs experienced in mid-2015. The extended consolidation period of 2 1/2 years has set up biotechs for a prolonged rally as it approaches the point of eclipsing the all-time high achieved in 2015. The Nasdaq Biotechnology Index, as repr…
Dosing underway in early-stage study of Agios Pharma's AG-270
The first patient has been dosed on a Phase 1 clinical trial assessing Agios Pharmaceuticals' ( AGIO -1.8% ) AG-270 in patients with solid tumors or lymphoma with a deletion of the MTAP gene. More news on: Agios Pharmaceuticals, Inc., Celgene Corporation, Healthcare stocks news, Re…
Biotechs: Still Well Placed For More Gains
Biotech Pulse The cold winds of February cut into the market as stocks found themselves going in an unaccustomed direction. Sliding like a toboggan on a ski slope, stocks last week experienced the sharpest correction in over 50 years, reaching the -10% mark within a week. This marked the d…
Your Daily Pharma Scoop: AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Celgene Reports Results For Otezla
Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss AbbVie ( ABBV ), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, …
3 Things In Biotech You Should Learn Today: February 18, 2018
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec…
Agios Pharmaceuticals, Inc. (AGIO)